Fibrin fibers form the structural backbone of blood clots. The structural properties of fibrin clots are highly dependent on formation kinetics. Environmental factors such as protein concentration, pH, salt, and protein modification, to name a few, can affect fiber kinetics through altered fibrinopeptide release, monomer association, and/or lateral aggregation. The objective of our study was to determine the effect of thrombin and fibrinogen exposed to nitric oxide on fibrin clot properties. ProliNONOate (5 mmol/l) was added to fibrinogen and thrombin before clot initiation and immediately following the addition of thrombin to the fibrinogen solution. Resulting fibrin fibers were probed with an atomic force microscope to determine their diameter and extensibility and fibrin clots were analyzed for clot density using confocal microscopy. Fiber diameters were also determined by confocal microscopy and the rate of clot formation was recorded using UV-vis spectrophotometry. Protein oxidation and S-nitrosation was determined by UVvis, ELISA, and chemiluminescence. The addition of ProliNONOate to fibrinogen or thrombin resulted in a change in clot structure. ProliNONOate exposure produced clots with lower fiber density, thicker fibers, and increased time to maximum turbidity. The effect of the exposure of nitric oxide to thrombin and fibrinogen were measured independently and indicated that each plays a role in altering clot properties. We detected thrombin S-nitrosation and protein carbonyl formation after nitric oxide exposure. Our study reveals a regulation of fibrin clot properties by nitric oxide exposure and suggests a role of peroxynitrite in oxidative modifications of the proteins. These results relate nitric oxide bioavailability and oxidative stress to altered clot properties. Blood Coagul Fibrinolysis 28:356-364
Introduction
Fibrin fibers are a major component in the structure of blood clots. They provide support to blood clots through the formation of a branching network of fibers. Fibrin fibers are formed from soluble fibrinogen after removal of fibrinopeptides A and B by the serine protease thrombin. Removal of fibrinopeptides A and B expose charged knobs, which interact with oppositely charged holes on the distal region of a different fibrin monomer. This charge-charge interaction leads to protofibril formation and is followed by lateral association resulting in fiber formation and ultimately a branched fiber network. Additional covalent bonds are formed between fibrin molecules by transglutaminase, factor XIIIa (FXIIIa), after polymerization.
Fibrin network properties, both structural and mechanical, are influenced by polymerization conditions, including thrombin concentration, fibrinogen concentration, methionine oxidation, pH, ionic strength, calcium concentration, and tyrosine nitration [1] [2] [3] [4] [5] [6] [7] [8] [9] . Structural changes at the single fiber and whole clot level affect the mechanical properties of fibrin clots. Li et al. [10] showed smaller fibrin fibers have higher individual moduli than larger fibers and Ryan et al. [9] showed fibrin clot modulus varies with fiber density, fiber diameter, fiber length, and branch point density [10, 11] . Structural and mechanical variations to the fibrin network alter the rate of clot fibrinolysis [12, 13] and alter cell infiltration and cellular biochemical function [14] . Altered network properties have been linked to clotting disorders and diseases such as hemorrhaging, thrombosis, myocardial infarction, and stroke [11, 15] . For example, myocardial infarction can be linked to an increased storage modulus, G [9, 15, 16] . Altered clot architecture has been linked to diabetes, chronic heart failure, and abdominal aortic aneurysms [17, 18] .
In this manuscript, we investigate the effect of nitric oxide exposure on fibrin clot properties. Supraphysiological levels of nitric oxide are known to affect the activity of factor XIIIa [19] and therefore the crosslinking for fibrin fibers. Here, we focus on the exposure of thrombin and fibrinogen to nitric oxide through nitric oxide donor, ProliNONOate. This study is motivated by the results of Davis et al. [20] who reported a decrease in detection of nitric oxide produced by endothelial cells in the presence of fibrin and suggested this decrease in nitric oxide was because of a fibrin-nitric oxide interaction.
The bioavailability and role of nitric oxide in cardiovascular signaling is a highly studied subject [21, 22] . Although nitric oxide was originally thought to be short lived in the blood stream, recent research suggests nitric oxide remains active in the blood stream through various mechanisms [23] [24] [25] [26] . For example, the effect of nitric oxide metabolite, nitrite, on blood flow suggests the reduction of nitrite to nitric oxide in the blood stream [27] . In addition to the direct interaction between nitric oxide and fibrin clots suggested by Davis et al. [7] , byproducts of nitric oxide can interact with proteins and lead to modifications such as nitration, carbonyl formation, and/or S-nitrosation.
Previous work looking at protein modifications has shown that fibrin tyrosine nitration increased clotting rate at low concentrations and decreased clotting rate at high concentrations [28] ; whereas thrombin tyrosine nitration decreased thrombin activity [29] . The physiological relevance of these modifications is supported by measurements of S-nitrosation of plasma proteins such as albumin at physiological nitric oxide concentrations as well as shown implications of hypo or hyper S-nitrosation of blood proteins in disease states [22, 30] . Similarly, studies reported protein nitration in many diseases such as cardiovascular diseases, Alzheimer's disease, and Parkinson's disease [31] [32] [33] . Specifically, nitrated fibrinogen is a risk factor in venous thromboembolism [34] .
In this article, we investigated the role of in-vitro nitric oxide exposure on fibrin clot properties and measured protein S-nitration, tyrosine nitration, and carbonyl formation. We determined nitric oxide exposure via ProliNONOate lead to these modifications.
Methods
All experiments were performed in fibrin buffer (pH 7.4, 10 mmol/l HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 5 mmol/l CaCl 2 , 140 mmol/l NaCl). Clots were formed from 1 mg/ml fibrinogen (Louisville APL Diagnostics, Doraville, Georgia, USA) mixed with fibrin buffer and 55 Loewy U/ml FXIIIa, where indicated, (Enzyme Research Laboratory, South Bend, Indiana, USA) and clotting was initiated with the addition of thrombin (Enzyme Research Laboratory).
Nitric oxide donor, ProliNONOate (Cayman Chemical, Ann Arbor, Michigan, USA) is stable in alkaline solutions but dissociates in a pH-dependent manner. Its half-life is 1.8 s at 378C in pH 7.4. Therefore, ProliNONOate was suspended in 0.01 NaOH at a stock concentration of 75 mmol/l and was added in small volumes to the indicated protein solutions with a final concentration of 5 mmol/l. ProliNONOate concentration was determined by absorbance at 252 nm. The addition of ProliNONOate to the protein samples raised the pH of the samples from 7.4 to 7.5 and therefore controls were run with an equal volume of NaOH added to the sample to rule out any pH effect.
To determine the effect of ProliNONOate on fibrin clot properties, 5 mmol/l ProliNONOate was added to fibrinogen prior to clot formation (fibrinogen þ nitric oxide), 5 mmol/l ProliNONOate was added to thrombin prior to clot formation (thrombin þ nitric oxide), or 5 mmol/l ProliNONOate was added to the clot solution immediately following the addition of thrombin and the solution was briefly mixed (all þ nitric oxide). Care was taken to perform this step quickly to avoid polymerization during mixing.
Fiber density by confocal microscopy Two #1.5 cover slides were coated with Sigmacote (Sigma-Aldrich, St. Louis, Missouri, USA) prior to clot formation. Fibrin clots were prepared from 1 mg/ml fibrinogen, comprised of 10% Alexa 488-labelled fibrinogen (Invitrogen, Grand Island, New York, USA) and 90% unlabeled fibrinogen in fibrin buffer. Clot formation was initiated by the addition of 1 NIH unit/ml thrombin to the fibrinogen solution. ProliNONOate was added as indicated above. Immediately following the addition of thrombin, the fibrin clot solution was placed on a coated cover slip inside a sealed humidity chamber. The clot was left to polymerize in the humidity chamber for 2 h at room temperature. Coverslips were then sealed in holders to minimize drying of samples during imaging. Confocal images were obtained within 24 h of clot initiation to ensure minimal buffer evaporation using a Leica SP2 inverted confocal microscope (Leica Microsystems Inc., Buffalo Grove, Illnois, USA) with a 63Â, 1.43 numerical aperture oil immersion lens using a 488 nm Argon laser. Regions of the clot were randomly selected and 30 slices of resolution 1024 Â 1024 pixels were taken at an interval of 0.25 mm in z. Images were obtained from three regions of each clot. A minimum of 12 clots were analyzed for each sample condition.
Image J software (NIH) was used to analyze the images. Fibrin fiber density of each images stack was determined as previously described by Hugenholtz et al. [35] . Briefly, lines were placed across the slices at 10-mm increments and averaging number of fibers intersecting the line were recorded. Fiber densities of three different regions per sample were averaged.
Fibrin fiber diameter by atomic force microscopy Fibrin fibers were formed on top of freshly cleaved mica by adding 0.5 NIH unit/ml thrombin to 1 mg/ml fibrinogen and ProliNONOate as indicated. The fibers polymerized in humidity controlled environment for 2 h before they were rinsed and air dried. The diameters of the dried fibrin fibers were determined by atomic force microscopy (AFM; Asylum Research, Santa Barbara, California, USA) using AC or intermittent contact mode. AFM scans were taken for a scan range of 5 mm Â 5 mm at a scan rate of 1 Hz and profile plots of line segments were used to determine fiber diameter. Tip contact with the fibers during scanning can compress the fibrin fibers therefore reducing fiber heights. Similarly, the conical shape of the tip causes tip-broadening effects increasing the width of the fibers. Therefore, we followed the procedure used by Domingues et al. [36] and measured the width of the fiber at half the maximum height to reduce error because of compression and tip broadening (Fig. 1) . A minimum of 69 fibers were imaged for each sample condition.
Fibrin fiber diameter by SEM In addition to AFM diameter measurement, we determined fibrin fiber diameters by scanning electron micrographs. Clots were formed on Sigmacote-treated glass slides with 0.5 IU/ml thrombin, 1 mg/ml fibrinogen, 55 units of factor XIII, and 5 mmol/l ProliNONOate or NaOH as indicated. Samples formed in a humid chamber for a minimum of 2 h before they were rinsed with HEPES buffer and fixed with a 2% gluteraldehyde solution for 30 min. The clots were rinsed and stained with a 1% osmium tetroxide solution for 15 min and rinsed again. Clots sat in dilutions of 50, 80, and 95% ethanol for 30 min each before being critical point dried (Tousimis, Rockville, Maryland, USA). The samples were sputter coated, mounted, and imaged on the Jeol SEM (JOEL USA, Peabody, Massachusetts, USA) at 10 kV.
Turbidity by UV-vis spectroscopy Clots were formed with 0.16 IU/ml thrombin and 5 mmol/ l ProliNONOate, as indicated, in disposable micro UV cuvettes (BrandTech Scientific, Essex, Connecticut, USA). Using a 10S Genesys UV-Vis Spectrophotometer (Thermo Scientific, Waltham, Massachusetts, USA), absorbance was measured at 350 nm every 10 s for 1-2 h. The measurements began immediately following the addition of thrombin. We calculated the initial rate of fiber polymerization (optical density or OD/s during the first minute after the lag period), the clotting rate (OD/s at 1 /2 max OD), and the clotting time (time at maximum slope; n ! 5). The first optical density measurement was used to baseline the data and the lag period was defined as the time before the OD increased beyond 0.05.
Extensibility by atomic force microscopy
The ridged substrate was formed from Norland optical adhesive 81 (Norland Products, Cranbury, New Jersey, USA) using soft lithography and a polydimethylsiloxane stamp as previously described [37, 38] . Fibrin fibers were formed on top of the 12-m wide ridges by adding 0.5 NIH u/ml thrombin and 5 mmol/l ProliNONOate as indicated. The sample polymerized for 2 h and then was rinsed with fibrinogen buffer to remove excess fibers. 24-nm carboxylated fluorescent beads (Life Technologies, Grand Island, New York, USA) were diluted in calcium-free fibrinogen buffer and were nonspecifically added to the sample. Fibers were visualized using an inverted fluorescence microscope (Zeiss, Thornwood New York, USA). Fibers were manipulated using an MFP-3D Bio AFM (Asylum Research, Santa Barbara, California, USA) and controlled step script allowing cantilever manipulation in the x, y, and z directions. Only fibers that were aligned perpendicular to or approximately perpendicular to the ridges were manipulated. An AFM cantilever was used to pull the fibrin fiber perpendicular to its orientation until it broke. To ensure that fibers were extended to their breaking points, samples that detached from the ridges were excluded. The process was recorded using a CCD camera and Zen software (AxioCam MRm; Zeiss, Peabody, Massachusetts, USA). The initial and final lengths of the fibers were measured from the video images. The strain was calculated for each sample by dividing the change in length by the initial length. The extensibility of at least 18 fibers was determined for each fiber formation condition.
Protein S-nitrosation by ozone chemiluminescence
Five micromole per litre ProliNONOate was added to 1 mmol/l protein. Protein S-nitrosation was measured by reductive chemiluminescence using the Nitric Oxide Analyzer (GE Analytical Instruments, Boulder, Colorado, USA). Aliquots of sample were injected into the coppercysteine assay, described previously [39] , in the purge vessel of the Nitric Oxide Analyzer to measure the nitric oxide released. The sample was treated with or without 5 mmol/l mercury chloride to ensure the signal was from S-NO bond.
Tyrosine nitration by ELISA Nitrotyrosine concentrations were measured using a commercially available nitrotyrosine competitive ELISA (Cell Biolabs Inc, San Diego, California, USA). 1 mg/ ml fibrinogen and 2 NIH unit/ml thrombin were exposed to 5 mmol/l ProliNONOate and were tested using the ELISA to quantify nitrotyrosine formation. The ELISA was completed as indicated by the instructions. Briefly, the samples and antinitrotyrosine antibody were added to the wells of a 96-well plate coated with nitrated BSA. After an incubation period, the wells were rinsed and a horseradish peroxidase secondary antibody was added for colorimetric detection. Absorbance measurements from the wells with the samples were compared with a nitrated BSA standard curve.
Carbonyl detection
Protein carbonyl concentration was determined by UVvis spectrophotometry using a simplified alkaline 2,4-dinitrophenylhydrazine (DNPH, TCI America, Portland, Oregon, USA) assay. Samples with 3 mg/ml fibrinogen or 20 mmol/l thrombin and 5 mmol/l ProliNONOate or equal volume NaOH were prepared and mixed in equal parts with 10 mmol/l DNPH. DNPH reacted with ketones or aldehydes to form a derivative with an absorbance peak around 370 nm, similar to the absorbance of free DNPH. The maximum wavelength of the hydrazine derivative was shifted by the addition of 1.2 mol/l NaOH and subsequent 10-min incubation, as described by Mesquita et al. [40] . Carbonyl concentrations were determined using a molar extinction coefficient of 22 308/mol/l/cm [40] .
Statistics
Data is reported as the mean AE SD unless indicated otherwise. Statistical significance was determined by performing a two-tailed, homoscedastic Student's t-test and P values are reported.
Results
We suspended ProliNONOate in NaOH for stability and prepared it at a high stock concentration to limit the amount of NaOH added to the samples during the addition of ProliNONOate. We added NaOH to the samples at a ratio of 1 part NaOH to 14 parts sample. The addition of NaOH to fibrin buffer at a ratio of 1 : 14 raised the pH from 7.4 to 7.5. Therefore, we added NaOH to control samples at a volume equal to that of ProliNONOate addition to account for any effect of pH control.
Additionally, because of assay limitations, the thrombin concentration changed between assays. We indicated thrombin concentration for each assay in the methods section. Therefore, one must take care when interpreting the results taken at various concentrations.
Clot density
Using confocal microscopy, we first tested for changes in clot density because of the addition of ProliNONOate. The addition of 5 mmol/l ProliNONOate immediately following the addition of thrombin to the fibrin clot solution (all þ nitric oxide) decreased the fiber density of the clot compared with controls (Fig. 2) . We noticed, by visual comparison, a decrease in fiber density of the sample image compared with the control image and confirmed the decrease quantitatively by determining the average number of fibers intersecting lines drawn across the image. On average, there were 10 AE 2 fibers (average AE SD) intersecting a 238-mm line passing through the nitric oxide þ all sample, whereas the control clot averaged 14 AE 5 fibers. The decreased fiber density was significant (P < 0.05).
To determine if the effect was because of an interaction of ProliNONOate with thrombin or fibrinogen, we tested ProliNONOate exposure to thrombin and fibrinogen independently. The addition of 5 mmol/l of ProliNONOate to thrombin, thrombin þ nitric oxide, or fibrinogen, fibrinogen þ nitric oxide, prior to clot formation significantly reduced the numbers of fibers intersecting a line to 9 AE 2 and 10 AE 5, respectively (P < 0.01 and P < 0.05). We measured a more significant effect of ProliNONOate addition to thrombin than to fibrinogen. Therefore, ProliNONOate had an effect on clot density through its interaction with both fibrinogen and thrombin.
Fiber diameter A decrease in clot fiber density may indicate an increase in fiber thickness. Therefore, we tested fibrin fiber diameter in clots in the presence and absence of ProliNONOate. Using AFM, we measured the full width of the fibers at half their maximum height to minimize compression and tip-broadening effects. Additionally, we measured fiber diameters in clots imaged by SEM.
Using both AFM and SEM, we measured an increase in fiber diameter under all conditions of ProliNONOate exposure (Fig. 1) . ProliNONOate added immediately following thrombin addition significantly increased fiber diameter determined by AFM from the control diameter of 135 AE 34 nm to 161 AE 41 nm (P < 0.01). We also measured a significant increase in fiber diameter when ProliNONOate was added to fibrinogen or thrombin independently. The addition of ProliNONOate to thrombin increased the fiber diameter determined by AFM to 168 AE 43 (P < 0.01, compared with control) and the addition ProliNONOate to fibrinogen increased AFM determined fiber diameter to 155 AE 37 (P < 0.01, compared with control).
We saw the same significant increases in fiber diameter when diameters were determined by SEM. Differences in the average diameters reported by the two techniques hint toward the independent limitations of the techniques. As mentioned above, the AFM requires contact during measurements and that contact can affect height and width measurements and similarly, sample dehydration needed for traditional SEM measurements can affect fiber diameters. However, the significant change in diameter was consistent through both techniques. As before, we saw a larger change in diameter when ProliNONOate was added to thrombin. However, the addition of ProliNONOate to both proteins affected fiber diameters.
Fiber formation kinetics
The measured changes in clot fiber density and diameter suggest altered fibrin polymerization kinetics. We measured the rate for fiber formation by UV-vis spectroscopy. The addition of nitric oxide to thrombin before clot initiation significantly decreased the initial rate of clot formation from (2.4 AE 0.6) Â 10 -3 OD/s to (1.3 AE 0.7) Â 10 -3 OD/s and increased the clotting time from 62 AE 20 s to 77 AE 30 s (P < 0.05, Fig. 3 , Table 1 ). The addition of nitric oxide to fibrin before clot formation trended toward a longer clotting time and a decreased initial rate of formation; however, the results were not significant (P > 0.05, Table 1 ).
Fiber extensibility
Changes in protofibril lateral aggregation can affect clot density, fiber diameter, and clot kinetics. Therefore, our data above support altered protofibril lateral aggregation. The mechanism behind alter protofibril lateral aggregation may be related to differences in molecular interaction between protofibrils or because of the concentration of fibrin present in solution, which can be altered by thrombin activity, thrombin concentration of fibrinogen concentration.
Fiber extensibility measurements may give some insight into altered molecular interactions between protofibrils. The mechanism of the extraordinary extensibility fibrin fibers is not completely known. Initial extensibility is thought to be because of extension of the coiled-coil region into b sheets and unfolding of the globular gC domains [38, 41, 42] . However, the lengthening because of these changes only account for a small portion of the fibers extensibility. One hypothesis is that further extension comes from aC extension and protofibril sliding [38, 41, 42] . Therefore, the strength of protofibril interactions may affect fiber extensibility.
To test this hypothesis, we measured the extensibility of fibrin fibers using an AFM (data not shown). We saw no change in extensibility when nitric oxide was added to clots during or prior to clot initiation (P > 0.05). Fibers formed in the absence of nitric oxide had an extensibility of 182 AE 36%. Fibers formed when nitric oxide was added to thrombin or fibrinogen prior to clot formation or when nitric oxide was added immediately following the addition of thrombin to the fibrinogen solution had average extensibilities ranging from 158 AE 59 to 201 AE 35%, none of which were significant when compared with the control. The extensibility measurements agree with previously reported values for cross-linked fibrin fibers [43] . 
Protein modification
To help explain the measured changes in clot fiber density, diameter, and kinetics with the addition of ProliNONOate, we tested the samples for protein oxidation and S-nitrosation. We repeated the protein modification assays in duplicate and report a weighted average. Under the sample conditions, we would not expect abundant formation protein S-nitrosation or oxidation products. Protein S-nitrosation requires the formation of a nitrosonium ion, NO þ , or transnitrosation from low molecular weight nitrosothiols such as S-nitrosocysteine [44] and oxidative products such as tyrosine nitration and carbonyl formation require superoxide and nitric oxide to form the species peroxinitrite.
As expected, when we used an ozone chemiluminescence system to measure protein S-nitrosation, we detected low fibrinogen nitrosylation, 6 AE 3 mmole S-nitrosothiol per mole of protein. Interestingly, a-thrombin contained 90 AE 40 mmole S-nitrosothiol per mole of protein.
Additionally, we used a competitive ELISA to measure protein tyrosine nitration and found 2 AE 2-mmole nitrated tyrosine per mole of fibrinogen and 160 AE 90-mmole nitrated tyrosine per mole of thrombin. The quantitative value of the nitration assay must be considered with some caution as the standard curve for tyrosine nitration used nitrated BSA and the affinity of the antibody for nitrated thrombin or fibrinogen may vary. Lastly, we measured carbonyl formation using an alkaline DNPH assay. With the addition of 5 mmol/l ProliNONOate carbonyl levels were below the detection limit of the assay; however, increasing ProliNONOate 10-fold, to 50 mmol/l produced 880 AE 480 mmol of carbonyls per mole of fibrinogen and 390 AE 80 mmol of carbonyls per mole of thrombin. This supports the assumption that carbonyls are produced through exposure of proteins to ProliNONOate. A summary of the results of the protein modification assays are shown in Table 2 . Thrombin has a larger amount of protein modifications in the tyrosine nitration and Snitrosylation assays. We believe this is because of the higher ProliNONOate concentration (5 mmol/l) to protein ratio for these thrombin samples (2 NIH unit/ ml or 18 nmol/l) compared with the corresponding fibrinogen samples (1 mg/ml or 2900 nmol/l). Confocal images of (a) a control sample, (b) a sample with 5 mmol/l ProliNONOate added at clot initiation (NO þ all), (c) a sample with 5 mmol/l ProliNONOate add to thrombin prior to clot initiation, (d) and a sample with 5 mmol/l ProliNONOate add to fibrinogen prior to clot initiation. All images were taken under the same magnification. (e) Lines spaced at 10 mm intervals were laid over the 238 Â 238 mm images and the average number of fibers intersecting a line was calculated to determine the fiber density of the clots. The graph displays the fiber density of clots formed under various conditions (average þ/À standard deviation, Ã P < 0.05, ÃÃ P < 0.01, n ranges from 13 to 20 clots).
Discussion
The addition of nitric oxide donor ProliNONOate to the fibrin clot following the addition of thrombin led to changes in the resulting fibrin clot. Fibrin clots formed in the presences of nitric oxide had a lower fiber density, larger fiber diameters, and had a slower rate of fiber formation. By testing the effect of ProliNONOate on fibrinogen and thrombin independently, we found that ProliNONOate exposure altered clots through interaction with fibrinogen and/or thrombin.
Changes in structural properties, like those reported in our data, are often the result of altered formation kinetics, which are because of changes in intermolecular interactions, thrombin activity, or thrombin or fibrinogen concentration. In regards to enzymatic activity, a decrease in thrombin activity is known to increase fibrin fiber diameter and decrease the fiber density of the clot [9, 45, 46] . In the presence of nitric oxide, we measured a decrease in the rate of polymerization, increase in fiber height by AFM and a decrease in fiber density of the clot, indicative of decreased thrombin activity. We measured 39% carbonyl formation and 9% S-nitrosation of thrombin. De Cristofaro et al. [47] reported a decrease in the catalytic efficiency of thrombin with oxidation and Lundbald et al. [29] showed a decrease of thrombin enzymatic activity with oxidation.
Additionally, we saw changes when nitric oxide was added directly to fibrinogen prior to clot initiation. The addition of nitric oxide to fibrinogen decreased clot density, increased fiber diameter, and decreased the rate of clot formation. The quantity of S-nitrosated and tyrosine-nitrated fibrinogen after nitric oxide exposure was low with 6 mmol of S-nitrosothiols per mole of protein; however, we measured a carbonyl concentration of 100 mmol per mole of fibrinogen. These data build on the changes in fibrin clot kinetics because of fibrinogen oxidation reported by Vadseth et al. [3] .
Vadseth et al. [3] reported a decrease in the initial rate of fiber formation with 1.5 carbonyls per fibrinogen monomer. This is consistent with our reported trend of a decrease in rate of clot formation. However, Vadseth et al. [3] also reported an increase in the rate of clot formation at very low levels of tyrosine nitration, approximately 8 mmol of nitrotyrosines per mole of proteins and data by Parastatidis et al. [2] measured an increase in the rate for fibrin formation, altered clot structure, increased fibrin stiffness, and a decrease in clot lysis in the presence of fibrinogen nitration.
Similar fibrinogen tyrosine nitration levels in our samples to those of Vadseth [3] did not lead to an increase rate of clot formation. We believe this is because of a balance between fibrinogen tyrosine nitration and fibrinogen carbonyls. The significant but smaller effect on fiber kinetics, diameter, and fibrin clot density of fibrinogen exposure to ProliNONOate when compared with thrombin may be because of the competing mechanisms of carbonyls and fibrinogen nitration.
Our results suggest that exposure of fibrinogen and thrombin to ProliNONOate lead to the measured clot changes through protein oxidation, which decreased the activity of thrombin and altered fibrin polymerization. However, the mechanism of oxidation upon nitric oxide exposure is unclear. A common pathway of protein oxidation requires the formation of peroxynitrite form nitric oxide and superoxide, which should only exist in trace quantities in our solution. Therefore, we will focus future work on identifying the mechanism of oxidation to ensure the changes in clot structure are indeed because of oxidation and not another nitric oxide protein interaction.
Nitric oxide is a small biological molecule produced by endothelial cells that line blood vessels. Its bioavailability is an active research area and varies substantially under disease conditions. Although the concentration of nitric oxide used in this study was high, elevated levels of tyrosine nitration has been measured in vivo [2, 3] .
Our data show nitric oxide exposure altered fibrin clot density, fiber diameter, and fiber formation kinetics. Measurement of protein oxidation suggests these changes are because of protein modifications. Previous studies report oxidative modifications to fibrinogen both increase and decrease the rate of fiber formation. Here, we show nitric oxide exposure leads to modifications that when considered cumulatively decrease the rate of fiber formation and consequently lead to associated structural changes. 
